Detailed Mechanism Funding and Narrative

Years of mechanism: 2013 2014 2015 2016 2017 2018

Details for Mechanism ID: 16854
Country/Region: Nigeria
Year: 2016
Main Partner: Center for Clinical Care and Clinical Research
Main Partner Program: NA
Organizational Type: NGO
Funding Agency: HHS/CDC
Total Funding: $4,906,228 Additional Pipeline Funding: $561,166

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $691,090
Care: Orphans and Vulnerable Children (HKID) $988,000
Care: TB/HIV (HVTB) $309,466
Care: Pediatric Care and Support (PDCS) $207,204
Laboratory Infrastructure (HLAB) $0
Strategic Information (HVSI) $0
Biomedical Prevention: Blood Safety (HMBL) $0
Biomedical Prevention: Injection Safety (HMIN) $0
Testing: HIV Testing and Counseling (HVCT) $0
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $720,501
Treatment: Adult Treatment (HTXS) $1,935,741
Treatment: Pediatric Treatment (PDTX) $54,226
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2017 17,073
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2017 15,139
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2017 177,787
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2017 54,220
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2017 264,219
HTS_TST Service Delivery Point (Facility): Index testing 2017 270
HTS_TST Service Delivery Point (Facility): Inpatient 2017 615
HTS_TST Service Delivery Point (Facility): Malnutrition facilities 2017 146
HTS_TST Service Delivery Point (Facility): Other PITC 2017 11
HTS_TST Service Delivery Point (Facility): Outpatient 2017 81,424
HTS_TST Service Delivery Point (Facility): Pediatric 2017 31,751
HTS_TST Service Delivery Point (Facility): PMTCT 2017 116,647
HTS_TST Service Delivery Point (Facility): TB Clinics 2017 3,005
HTS_TST Service Delivery Point (Facility): VCT 2017 30,350
HTS_TST Sum of Aggregated Age/Sex <15 2017 32,212
HTS_TST Sum of Aggregated Age/Sex 15+ 2017 232,007
HTS_TST Sum of Aggregated Age/Sex disaggregates 2017 264,219
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Female 2017 227
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Male 2017 164
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Female 2017 2,089
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Male 2017 1,786
LAB_PT CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 25
LAB_PT CD4: Number of laboratories that participate in this PT program 2017 28
LAB_PT CD4: Number of laboratories that perform this testing 2017 28
LAB_PT Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 1
LAB_PT Early infant diagnostics: Number of laboratories that participate in this PT program 2017 1
LAB_PT Early infant diagnostics: Number of laboratories that perform this testing 2017 1
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 25
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program 2017 28
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that perform this testing 2017 28
LAB_PT HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 1
LAB_PT HIV viral load: Number of laboratories that participate in this PT program 2017 1
LAB_PT HIV viral load: Number of laboratories that perform this testing 2017 1
OVC_SERV Age/Sex: 18+ Female 2017 11,270
OVC_SERV Age/Sex: 18+ Male 2017 1,251
OVC_SERV By Aggregated Age/Sex: <18 Female 2017 11,271
OVC_SERV By Aggregated Age/Sex: <18 Male 2017 1,253
OVC_SERV Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS 2017 25,045
OVC_SERV Sum of Age/Sex disaggregates 2017 12,521
PMTCT_ART Already on ART at beginning of current pregnancy 2017 852
PMTCT_ART New on ART 2017 1,334
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 116,489
PMTCT_EID By infants who received a virologic test within 2 months of birth 2017 1,619
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2017 568
PMTCT_EID Number of infants with a positive virological test result within 12 months of birth 2017 17
PMTCT_EID Number of infants with a positive virological test result within 2 months of birth 2017 43
PMTCT_EID Sum of Infant Age disaggregates 2017 2,187
PMTCT_STAT By: Known positives at entry 2017 911
PMTCT_STAT By: Number of new positives identified 2017 1,384
PMTCT_STAT Number of new ANC and L&D clients 2017 122,786
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 116,489
PMTCT_STAT Sum of Positives Status disaggregates 2017 2,295
TB_ART Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 1
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 114
TB_ART Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 1
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 119
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2017 262
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2017 235
TB_SCREENDX [Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB 2017 758
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay 2017 684
TB_SCREENDX Screen Result: Screened Positive for TB 2017 842
TB_SCREENDX Screened for TB by Age/Sex: 15+ Female 2017 25,525
TB_SCREENDX Screened for TB by Age/Sex: 15+ Male 2017 9,758
TB_SCREENDX Screened for TB by Age/Sex:<15 Female 2017 410
TB_SCREENDX Screened for TB by Age/Sex:<15 Male 2017 970
TB_SCREENDX The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period 2017 36,663
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 29
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 580
TB_STAT Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 33
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 722
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2017 1,364
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2017 1,515
TX_CURR Aggregated Age/Sex: <15 Female 2017 756
TX_CURR Aggregated Age/Sex: <15 Male 2017 925
TX_CURR Aggregated Age/Sex: 15+ Female 2017 23,498
TX_CURR Aggregated Age/Sex: 15+ Male 2017 10,428
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2017 35,607
TX_CURR Sum of Aggregated Age/Sex <15 2017 1,681
TX_CURR Sum of Aggregated Age/Sex 15+ 2017 33,926
TX_CURR Sum of Aggregated Age/Sex disaggregates 2017 35,607
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2017 120
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2017 104
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2017 2,273
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2017 1,976
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2017 4,473
TX_NEW Sum of Aggregated Age/Sex disaggregates 2017 4,473
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2017 35,606
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2017 32,048
TX_PVLS Numerator Aggregated Age/Sex: <15 Female 2017 836
TX_PVLS Numerator Aggregated Age/Sex: <15 Male 2017 910
TX_PVLS Numerator Aggregated Age/Sex: 15+ Female 2017 21,110
TX_PVLS Numerator Aggregated Age/Sex: 15+ Male 2017 9,192
TX_PVLS Numerator: Indication: Routine 2017 25,638
TX_PVLS Numerator: Indication: Targeted 2017 6,410
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Female 2017 930
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Male 2017 1,013
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Female 2017 23,452
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Male 2017 10,211
TX_PVLS_den Denominator: Indication: Routine 2017 28,485
TX_PVLS_den Denominator: Indication: Targeted 2017 7,121
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 102
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 110
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 2,951
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 1,314
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2017 4,477
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2017 5,267
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 116
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 138
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 3,477
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 1,536
Cross Cutting Budget Categories and Known Amounts Total: $938,764
Human Resources for Health $581,808
Economic Strengthening $50,145
Food and Nutrition: Commodities $60,201
Gender: Gender Based Violence (GBV) $201,610
GBV Prevention
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Post GBV Care
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Gender: Gender Equality $45,000
Changing harmful gender norms and promoting positive gender norms
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Increase gender-equitable access to income and productive resources, including education
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Equity in HIV prevention, care, treatment and support
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation